S100A1 Gene Therapy Preserves in Vivo Cardiac Function after Myocardial Infarction-Reference-Cited by-同舟云学术

S100A1 Gene Therapy Preserves in Vivo Cardiac Function after Myocardial Infarction

Published:2005-12 Issue:6 Volume:12 Page:1120-1129
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Pleger Sven T.,Remppis Andrew,Heidt Beatrix,Völkers Mirko,Chuprun J. Kurt,Kuhn Matthew,Zhou Rui-Hai,Gao Erhe,Szabo Gabor,Weichenhan Dieter,Müller Oliver J.,Eckhart Andrea D.,Katus Hugo A.,Koch Walter J.,Most Patrick

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference35 articles.

1. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research;Cohn;Circulation,1997

2. Heart disease and stroke statistics,2004

3. S100a0 (alpha alpha) protein: distribution in muscle tissues of various animals and purification from human pectoral muscle;Kato;J. Neurochem.,1986

4. S100A1: a regulator of myocardial contractility;Most;Proc. Natl. Acad. Sci. USA,2001

5. Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance;Most;J. Biol. Chem.,2003

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy;Cardiovascular Diabetology;2023-02-20

2. SUMO interacting motif (SIM) of S100A1 is critical for S100A1 post-translational protein stability;2023-01-19

3. Beta-3 adrenergic receptor overexpression reverses aortic stenosis–induced heart failure and restores balanced mitochondrial dynamics;Basic Research in Cardiology;2022-11-29

4. Lycium barbarum polysaccharide antagonizes cardiomyocyte apoptosis by inhibiting the upregulation of GRK2 induced by I/R injury, and salvage mitochondrial fission/fusion imbalance and AKT/eNOS signaling;Cellular Signalling;2022-04

5. In vivo therapeutic genome editing via CRISPR/Cas9 magnetoplexes for myocardial infarction;Biomaterials;2022-02